Composite Functional Genetic and Comedication CYP2D6 Activity Score in Predicting Tamoxifen Drug Exposure Among Breast Cancer Patients
Silvana Borges(Indiana University School of Medicine), Lang Li(Nanjing Agricultural University), Todd C. Skaar(Indiana University School of Medicine), Anne Nguyen(Indiana University School of Medicine), James M. Rae(University of Michigan), Vered Stearns(Johns Hopkins University), Daniel F. Hayes(University of Michigan–Ann Arbor), Zeruesenay Desta(Indiana University School of Medicine), Yan Jin(Indiana University School of Medicine), David A. Flockhart(Indiana University – Purdue University Indianapolis), Jason Robarge(Washington University in St. Louis), Santosh Philip(Indiana University School of Medicine), Faouzi Azzouz(Indiana University Health)
Cited by 128
Related Papers
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.3k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k
Revision of the American Joint Committee on Cancer Staging System for Breast Cancer
|Journal of Clinical Oncology|2002|1.2k
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
|Nature Genetics|2013|1.2k